Latest News


News Archive

2017 - 2018
  • Press Release: Affordable Healthcare in Oulu Closer than Ever: Paras Biopharmaceuticals Finland Oy Significantly Invests in Oulu Biologics Production Site
  • Paras Biopharmaceuticals acquires new Agilent Q-TOF to expand analytical capabilities
  • Paras Biopharmaceuticals receives Quality Choice award from European Society for Quality Research, Switzerland
  • Biochemistry Students participate in fact-finding tour of Microbial Biologics Production facility
  • New team members join Paras Biopharmaceuticals.
  • Paras Biopharmaceuticals upgrades its purification suite to expand existing capabilities.
  • Paras Biopharmaceuticals expands its purification suite with the addition of low-pressure AxiChrom columns from GE Healthcare Life Sciences.
  • Oulu-based Paras Biopharmaceuticals develops technology for Osteoporosis biosimilar drug & brings international investments. Expansion scheduled in Oulu.
2015 - 2016
  • Paras Biopharmaceuticals Finland Oy Selected as First Finnish Company to Present at Cavendish Global Health Impact Forum.
  • Paras Biopharmaceuticals wins the 2014 European Biopharmaceuticals Technology Innovation Leadership Award by Frost & Sullivan.
  • Paras achieves quality, bio efficacy and potency in its Forteo Biosimilar product. Clinical studies to begin.
  • Dr Hans Söderlund, Director of Global Strategic Alliance will be the Key-note speaker at "Reshaping Human Life Through Biotechnology" conference organised by the Gujarat State Biotechnology Mission (GSBTM), Mahatma Mandir, Gandhinagar.
  • Paras Biopharmaceuticals facilities in Finland upgraded with additional equipment.
  • New team members join Paras Biopharmaceuticals in its efforts to double-up and deliver quality biotherapeutics.
  • Paras’ labs achieve high titers and production expression levels for anti-diabetic and osteoporosis recombinant therapeutic proteins.
  • Paras Biopharmaceuticals expands its core- team of management professionals. Looking for strategic tie ups on technology licensing.
  • Paras Biopharmaceuticals representative participates in “Business Innovations in Global Healthcare Program” in Harvard Business School (HBS), Boston, M.A, USA.
  • Paras Biopharmaceuticals Finland Oy successfully develops long acting analog insulin – Biosimilar with very high yield and process which gives way for its economical production at industrial scale.
  • Clones developed by Paras Biopharmaceuticals Finland Oy stored in additional location in Germany.
  • Paras Biopharmaceuticals Finland Oy completes Diabrid Expressions, visualization of Diabrid in E. Coli.
2012 - 2013
  • The company achieves New Diabrid expressions and purification for therapeutic peptides/biologics of high value.
  • Company filing PCT patents on Diabrid technology.
  • Company invited to participate in Jefferies Global Healthcare Investment meets in New York (June 3-6, 2013).
  • Technology development team of Paras achieves robust Crystals for Rheumatoid Arthritis product.
  • Company team makes a successful trip to India to shortlist Joint Venture partner.
  • Company in advanced discussion with technology licensing.